Aiforia Technologies Plc – Managers’ Transactions

Report this content

Aiforia Technologies Plc

COMPANY RELEASE, MANAGERS’ TRANSACTIONS 3 June 2022 09.00 a.m. EEST

___________________________________________________________

 

Person subject to the notification requirement

Name: Jukka Tapaninen

Position: Chief Executive Officer

 

Issuer: Aiforia Technologies Oyj

LEI: 743700TJRVBX7420Y723

Notification type: INITIAL NOTIFICATION

Reference number: 15792/5/6

___________________________________________________________

 

Transaction date: 2022-05-31

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000507934

Nature of the transaction: ACQUISITION

 

Transaction details

 

(1): Volume: 97 Unit price: 4.72 EUR

(2): Volume: 100 Unit price: 5 EUR

(3): Volume: 118 Unit price: 4.72 EUR

(4): Volume: 100 Unit price: 5 EUR

(5): Volume: 419 Unit price: 4.8 EUR

Aggregated transactions

(5): Volume: 834 Volume weighted average price: 4.82734 EUR

 

___________________________________________________________

 

Transaction date: 2022-06-01

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000507934

Nature of the transaction: ACQUISITION

 

Transaction details

 

(1): Volume: 450 Unit price: 5.02 EUR

(2): Volume: 100 Unit price: 5.1 EUR

Aggregated transactions

(2): Volume: 550 Volume weighted average price: 5.03455 EUR

___________________________________________________________

 

Further enquiries

 

Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc, tel. +358405009878

https://investors.aiforia.com/

 

Certified Adviser

 

UB Securities Ltd, tel. +358 9 25 380 225

 

About Aiforia

 

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more. Find out more: www.aiforia.com